Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
26 Septembre 2023 - 5:01AM
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage
immunology company dedicated to enabling normal lives for people
with autoimmune diseases, today announced that it will report
initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023.
Following the announcement, the Company will host a conference call
and webcast at 8:00 a.m. ET to discuss the results.
To participate in the conference call, please register in
advance here. To access the live and archived webcast, please visit
Immunovant’s website at
https://www.immunovant.com/investors/news-events. The archived
webcast will be available for a limited time on the Company’s
website.
About Immunovant, Inc.Immunovant, Inc. is a
clinical-stage immunology company dedicated to enabling normal
lives for people with autoimmune diseases. As a trailblazer in
anti-FcRn technology, the Company is developing innovative,
targeted therapies to meet the complex and variable needs of people
with autoimmune diseases. For additional information on the
Company, please visit www.immunovant.com.
Contact:Chau Cheng, PhD, MBAVice President,
Investor RelationsImmunovant, Inc.info@immunovant.com
Immunovant (NASDAQ:IMVT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Immunovant (NASDAQ:IMVT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
